Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa plus standard chemotherapy regimens in cervical cancer
jRCT2080225362Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of bintrafusp alfa in Cervical Cancer (CC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Safety and tolerability of bintrafusp alfa combinations. Started Aug 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080225362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225362.